Clinical trials: Malaria Vivax
Malaria
Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax
This is a randomized, double-blind, controlled, which seeks to compare two groups of volunteers (naive and previously exposed to malaria) who were made 3 immunizations with a synthetic derivative of the CS protein of Plasmodium…
- Trial name
- NCT02083068
- Testing
- Vaccine PvCS N+C+R, Vaccine PvCS N+C, SSN Montanide ISA-51
- Where
- Colombia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria, Vivax
Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1
This is an Open label, first-in-human, Phase I/IIa, blood-stage P. vivax malaria vaccine trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium vivax malaria vaccine candidate PvDBPII in Matrix M1…
- Trial name
- NCT04201431
- Testing
- PvDBPII/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Vivax
VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP Vaccines
This is an open label, Phase IIa, controlled human malaria infection (CHMI) study aimed to assess whether the new vivax malaria vaccines ChAd63 PvDBP and MVA PvDBP can protect against malaria infection.
- Trial name
- NCT04009096
- Testing
- ChAd63 PvDBP and MVA PvDBP
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Plasmodium Vivax
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
This is a first-in-humans safety, immunogenicity and efficacy study with recombinant protein VMP001, a Plasmodium vivax circumsporozoite (CS) protein based vaccine.
- Trial name
- NCT01157897
- Testing
- VMP001, P. vivax sporozoite challenge
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Vivax Malaria
Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects
This is a standard pharmacokinetic interaction study. Subjects will be randomized to be either group A or B. Group A. Subjects will have 3 hospitalizations to complete.
- Trial name
- PQCQ (NCT01218932)
- Testing
- A, B
- Where
- Thailand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil
Background: The World Health Organization recommends that antimalarial treatment policies be evaluated every few years to check their efficacy. P.
- Trial name
- NCT02043652
- Testing
- Chloroquine, Primaquine
- Where
- Brazil
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Malaria, Vivax
Serological Screen and Treat Trial for Plasmodium Vivax
This is a clinical trial to evaluate an experimental serological diagnostic technique intended to identify people at high risk of having dormant malaria parasites in their liver.
- Trial name
- SSAT (NCT04223674)
- Testing
- Serological screen and treat
- Where
- Indonesia
- Volunteers
- 1,133 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Malaria Vivax
Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection
- Trial name
- Vivaxin-001 (NCT07172724)
- Testing
- Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Malaria
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites
It is possible to safely protect human volunteers immunized with P. vivax irradiated sporozoites from P. vivax challenge with live sporozoites.
- Trial name
- SPZ-Irrad (NCT01082341)
- Testing
- Immunization with P. vivax irradiated sporozoites
- Where
- Colombia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Malaria Prevention Cambodia
Trial of monthly DHA-piperaquine for malaria prevention in health volunteers.
- Trial name
- MPC (NCT01624337)
- Testing
- DHA-piperaquine
- Where
- Cambodia
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Healthy Lactating Women
Tafenoquine and Primaquine in Colostrum and Breast Milk
Each year almost a million infants are born small for gestational age due to malaria infection in pregnancy. These infants are at risk for stillbirth or neonatal death, and being born too small predisposes the survivors to…
- Trial name
- TBM (NCT04984759)
- Testing
- Primaquine, Tafenoquine
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Oxford
MALARIA, FEVER
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
The study is a randomized open label clinical trial to verify the reproducibility of a sporozoite challenge model for Plasmodium vivax in humans.
- Conditions
- MALARIA, FEVER, Sweating Fever, Chills
- Trial name
- NCT00367380
- Testing
- 413ABM, 414WRR, 418JAL
- Where
- Colombia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Plasmodium Vivax Infection
A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
The primary objectives of this study are to assess the safety and feasibility of blood-stage controlled human P. vivax malaria infection (CHMI) in healthy adult Thai volunteers through experimental injection of cryopreserved P.
- Trial name
- MIST2 (NCT05071079)
- Testing
- An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Vivax Malaria
Biomarkers of P. Vivax Relapse
Plasmodium vivax malaria is difficult to manage because even after taking medicine that kills the infection in the blood, it can continue to hide quietly in the liver, later re-emerging into the blood and causing another episode…
- Conditions
- Malaria, Vivax Malaria, Relapse, CYP2D6 Polymorphism
- Trial name
- NCT04228315
- Testing
- Primaquine
- Where
- Thailand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Malaria, Vivax, G6PD Deficiency
Assessing a Risk Model for G6PD Deficiency
A clinical study designed to develop and inform an individual risk of hemolysis model based on individual red blood cell G6PD levels.
- Trial name
- NCT03337152
- Testing
- primaquine, chloroquine + primaquine
- Where
- Thailand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Vivax
A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate
This will be a single-centre, 5-cohort, randomized open-label, parallel-group study in healthy volunteer subjects. This study aims to provide sufficient pharmacokinetic (PK) evidence to support the safe usage of Tafenoquine (TQ)…
- Trial name
- NCT02184637
- Testing
- Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Vivax
Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants
This was a phase I double blind controlled vaccine trial, evaluating safety, tolerability and immunogenicity of mixtures of N, R and C LSP derived from the P.
- Trial name
- Fase1B (NCT01081847)
- Testing
- Peptides (N,R&C) formulated in Montanide ISA 720, Peptides (N,R&C) formulated in Montanide ISA 51
- Where
- 2 sites in Colombia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode
Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity
This study specifically seeks to quantify the contribution of relapes to the burden of P. vivax infections and disease by determining on the effect of radical pre-erythrocytic and erythrocytic clearance on subsequent rates of…
- Conditions
- Plasmodium Vivax Infection, Plasmodium Vivax Clinical Episode, Plasmodium Falciparum Infection, Plasmodium Falciparum Clinical Episode
- Trial name
- NCT02143934
- Testing
- Primaquine, Chloroquine, Artemether Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 524 people, healthy volunteers welcome
- Sponsor
- Papua New Guinea Institute of Medical Research
Plasmodium Vivax Malaria, Plasmodium Vivax Infection
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
This clinical study will evaluate an investigational malaria vaccine called PvCS/Montanide ISA-51 to determine whether it is safe and whether it can protect adults from infection with Plasmodium vivax, one of the main parasites…
- Conditions
- Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention
- Trial name
- PvCS/M51 (NCT07373301)
- Testing
- PvCS/Montanide ISA-51 VG Vaccine
- Where
- Colombia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Malaria
Malaria Studies in Cambodia
This study, conducted by the National Center for Parasitology, Entomology and Malaria Control of Cambodia s Ministry of Health and the National Institute of Allergy and Infectious Diseases, will explore whether the following…
- Trial name
- NCT00663546
- Where
- 3 sites in Cambodia
- Volunteers
- 1,978 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)